Tianjing Biotech and Sinopharm Group reached a strategic cooperation to help China's innovative business transformation to benefit patients

Tianjing Biotech announced that it has reached a commercial strategic cooperation with Sinopharm Holding Co.
, Ltd.
, and authorized more than 300 subsidiaries of Sinopharm Holding Group as distributors to carry out retail allocation and terminal sales, and carry out all-round cooperation on key projects to jointly promote Highly differentiated, "best-in-class" and even "world's first" products will enter the Chinese market as soon as possible to meet the actual treatment needs of patients
.

Tianjing Bio has a rich pipeline of innovative products, and many of its products have entered the pre-commercial preparation stage
.

Mr.
Zhu Yifei, Chief Commercial Officer of Tianjing Bio, said: “Sinopharm is a leader in China's pharmaceutical supply chain, distribution and retail industry, and has rich drug access resources and experience
.

Mr.
Liu Yong, President of Sinopharm Group, said: “Since its establishment in 2016, Tianjing Bio has rapidly grown into one of the most innovative biotechnology companies in China
.

According to this strategic cooperation agreement, Tianjing Bio will draw on Sinopharm’s mature experience in market access, bidding and networking, as well as its leading supply chain capabilities and the policy advantages of the Lingang Free Trade Zone.